Vosoritide
Overview
Vosoritide is a peptide drug developed for the treatment of achondroplasia, a common form of dwarfism. It works by targeting the natriuretic peptide receptor to modulate the growth signaling pathways.
API suppliers (1)
Suppliers of Vosoritide evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
- APICORE LLC (A WHOLLY OWNED SUB OF RK PHARMA INC)1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Vosoritide expires 11 Jul 2042 and exclusivity 20 Oct 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Vosoritide? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.